Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the...

UPPSALA, Sweden, Jan. 10, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic rhinitis when treated with Orexo´s nasal rescue medication including powder-based epinephrine, OX640.

The study was a cross-over study in 30 subjects assessing absorption and pharmacodynamic effects of epinephrine from two doses of OX640, with one of the doses also administered during ongoing allergic rhinitis symptoms. Exposure was compared to a commercial intramuscular injection.

Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. Absorption under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with significant airway symptoms. OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for treatment of anaphylaxis.

Systemic safety was in line with the known pharmacology of epinephrine and local effects were transient and tolerated. There were no severe or serious adverse events.

Robert Rönn, SVP and Head of R&D, said: "We are pleased with the outcome of the study which further support the utility of our OX640 epinephrine nasal powder for treatment of anaphylaxis, even in case of allergic rhinitis symptoms. Importantly, the study results allow us to decide on the final commercial formulation and dose, which is critical to advance the project towards regulatory approval. The data further reinforces our view that OX640 has the potential to be a unique and differentiated needle-free epinephrine product."

For further information please contact:Nikolaj Sørensen, President and CEOLena Wange, IR & Communications DirectorRobert Rönn, SVP and Head of R&DTel: +46 (0)18 780 88 00E-mail: [email protected]

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the U.S. market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the U.S.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.

About AmorphOX®

Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.

About study OX640-002

The study was a 4-period cross-over study in 30 otherwise healthy subjects with seasonal allergic rhinitis. The study was conducted off allergy season with no ongoing allergy symptoms in subjects. Epinephrine plasma levels, blood pressure and heart rate were collected after administration of two different doses of OX640 and 0.3 mg intramuscular epinephrine. In one treatment period, one of the OX640 doses was administered following nasal administration of allergens, producing acute allergic rhinitis symptoms in the subjects.

The information was submitted for publication at 2.00 pm CET on January 10, 2025.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/orexo/r/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-alle,c4089172

The following files are available for download:

https://mb.cision.com/Main/694/4089172/3197286.pdf

PR_Orexo announces positive topline data from clinical study of OX640_Jan 10 2025

SOURCE Orexo

ORXOY

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

<article style="font-family: Arial, sans-serif; line-height: 1.5; padding: 20px;">
    <h1 style="font-size: 24px; color: #333;">UPPSALA, Sweden, Jan. 10, 2025 /PRNewswire/ --</h1>
    <p style="font-size: 16px; color: #444;">Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic rhinitis when treated with Orexo´s nasal rescue medication including powder-based epinephrine, OX640.</p>
    
    <p style="font-size: 16px; color: #444;">The study was a cross-over study in 30 subjects assessing absorption and pharmacodynamic effects of epinephrine from two doses of OX640, with one of the doses also administered during ongoing allergic rhinitis symptoms. Exposure was compared to a commercial intramuscular injection.</p>
    
    <p style="font-size: 16px; color: #444;">Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. Absorption under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with significant airway symptoms. OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for treatment of anaphylaxis.</p>
    
    <p style="font-size: 16px; color: #444;">Systemic safety was in line with the known pharmacology of epinephrine and local effects were transient and tolerated. There were no severe or serious adverse events.</p>

    <blockquote style="font-size: 16px; color: #333; border-left: 4px solid #007BFF; padding-left: 10px; margin: 20px 0;">Robert Rönn, SVP and Head of R&D, said: "We are pleased with the outcome of the study which further support the utility of our OX640 epinephrine nasal powder for treatment of anaphylaxis, even in case of allergic rhinitis symptoms. Importantly, the study results allow us to decide on the final commercial formulation and dose, which is critical to advance the project towards regulatory approval. The data further reinforces our view that OX640 has the potential to be a unique and differentiated needle-free epinephrine product."</blockquote>

    <p style="font-size: 16px; color: #444;">For further information please contact:</p>
    <ul style="font-size: 16px; color: #444; padding-left: 20px;">
        <li>Nikolaj Sørensen, President and CEO</li>
        <li>Lena Wange, IR & Communications Director</li>
        <li>Robert Rönn, SVP and Head of R&D</li>
        <li>Tel: +46 (0)18 780 88 00</li>
        <li>Email: <a href="mailto:[email protected]" style="color: #007BFF;">[email protected]</a></li>
    </ul>

    <h2 style="font-size: 20px; color: #333;">About Orexo</h2>
    <p style="font-size: 16px; color: #444;">Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the U.S. market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the U.S.</p>

    <p style="font-size: 16px; color: #444;">For more information on Orexo, visit <a href="http://www.orexo.com" style="color: #007BFF;">www.orexo.com</a>. Follow Orexo on X, LinkedIn, and YouTube.</p>

    <h2 style="font-size: 20px; color: #333;">About AmorphOX®</h2>
    <p style="font-size: 16px; color: #444;">Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles that are built using a unique combination of a drug, carrier materials, and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.</p>

    <h2 style="font-size: 20px; color: #333;">About study OX640-002</h2>
    <p style="font-size: 16px; color: #444;">The study was a 4-period cross-over study in 30 otherwise healthy subjects with seasonal allergic rhinitis. The study was conducted off allergy season with no ongoing allergy symptoms in subjects. Epinephrine plasma levels, blood pressure, and heart rate were collected after administration of two different doses of OX640 and 0.3 mg intramuscular epinephrine. In one treatment period, one of the OX640 doses was administered following nasal administration of allergens, producing acute allergic rhinitis symptoms in the subjects.</p>

    <p style="font-size: 16px; color: #444;">The information was submitted for publication at 2.00 pm CET on January 10, 2025.</p>

    <p style="font-size: 16px; color: #444;">This information was brought to you by Cision <a href="http://news.cision.com" style="color: #007BFF;">http://news.cision.com</a>.</p>

    <p style="font-size: 16px; color: #444;"><a href="https://news.cision.com/orexo/r/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-alle,c4089172" style="color: #007BFF;">https://news.cision.com/orexo/r/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-alle,c4089172</a></p>

    <p style="font-size: 16px; color: #444;">The following files are available for download:</p>
    <p style="font-size: 16px; color: #444;"><a href="https://mb.cision.com/Main/694/4089172/3197286.pdf" style="color: #007BFF;">https://mb.cision.com/Main/694/4089172/3197286.pdf</a></p>

    <p style="font-size: 16px; color: #444;">PR_Orexo announces positive topline data from clinical study of OX640_Jan 10 2025</p>

    <p style="font-size: 16px; color: #444;">SOURCE Orexo</p>
</article>

Orexo's OX640 shows rapid epinephrine absorption in allergic rhinitis patients.
Topline data indicates OX640's efficacy exceeds intramuscular injection.
No severe adverse events reported during the clinical study.
OX640's formulation supports regulatory approval for anaphylaxis treatment.
Current sales reached SEK 639 million in 2023.

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

Information

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Research Analysis

Related News